TD Cowen analyst Ritu Baral reiterated a Buy rating and $390.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at H.C. WainwrightFebruary 27, 2025 6:05 AM Madrigal Pharmaceuticals (MDGL) PT Raised to $469 at CitiFebruary 26, 2025 3:52 PM Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on RevenueFebruary 26, 2025 7:05 AM Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with CompeFebruary 26, 2025 7:00 AM Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASHFebruary 26, 2025 6:30 AM